GSK

The data gives momentum to GSK’s fast-growing oncology business.

GSK sees blockbuster potential in targeted cancer therapy after promising early data

In September 2025, GSK said that Luke Miels (above) would replace Emma Walmsley as chief executive officer.

GSK profit lifted by HIV, asthma drugs in boost to new CEO

GSK said it will pay US$1.2 billion upfront for the drug, called efimosfermin, with potential for additional milestone payments totalling US$800 million.

GSK to buy liver disease drug for as much as US$2 billion

Sensodyne maker Haleon has agreed to buy back 44 million shares from Pfizer (top), currently its largest shareholder, with 618 million shares being sold to institutional investors.

Pfizer sells entire Haleon stake for US$3.24 billion

GSK boosted its 2031 sales forecast to over £40 billion, up from the more than £38 billion it previously expected.

GSK plans £2 billion share buyback, boosts long-term outlook

Investors are concerned about GSK’s pipeline and recent lower-than-expected sales of its RSV and shingles vaccines.

GSK to buy US cancer biotech IDRx for up to US$1.15 billion

GSK expects to record a £1.8 billion charge in its third quarter results due to the settlements, with no impact on its investment plans.

GSK surges 6.5% after US$2.2 billion Zantac lawsuits settlement

The over-the-counter treatment, known also by its non-commercial name ranitidine, was manufactured by several rivals including the French group Sanofi and US drugmaker Pfizer before it was withdrawn in 2019.

GSK wins latest US litigation over Zantac drug saga

GSK reported second-quarter core earnings of 43.4 pence per share on sales of £7.88 billion.

GSK raises annual profit and sales forecast after second quarter beat